Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099005 | 0.86 | TP53 (0.35) | TP53 | |
| SCHEMBL4101858 | 0.81 | L3MBTL1 (0.35) | NPC1RAB9AL3MBTL1KDM4C | |
| SCHEMBL4101183 | 0.78 | TP53 (0.35) | TP53 | |
| SCHEMBL4090468 | 0.75 | MAPT (0.39) | NPC1RAB9ATP53 | |
| SCHEMBL4102167 | 0.72 | TP53 (0.37) | TP53 | |
| SCHEMBL4105507 | 0.72 | GRIN1 (0.42) | — | |
| SCHEMBL4102486 | 0.70 | MAPT (0.34) | TP53 | |
| SCHEMBL4096300 | 0.70 | P2RX7 (0.37) | TP53 | |
| SCHEMBL4097982 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL4098135 | 0.67 | MAP4K1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | NPC1 1996/4885RAB9A 1821/4885MET 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.